PMADS

Id:	acc3149
Group:	2sens
Protein:	Cdc25C
Gene Symbol:	CDC25C
Protein Id:	P30307
Protein Name:	MPIP3_HUMAN
PTM:	phosphorylation
Site:	Ser198
Site Sequence:	EISDELMEFSLKDQEAKVSRS
Disease Category:	Cancer
Disease:	Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline:	Hep3B
Disease Info:
Drug:	HKH40A
Drug Info:	"HKH40A is a drug with potential medical applications, although specific details about it are not provided."
Effect:	modulate
Effect Info:	"Inhibiting the activity of Cdc25C through Chk1/2 - mediated inhibitory phosphorylation leads to the phosphorylation of downstream Cdk1 and cell cycle G2/M arrest, thereby inducing cell apoptosis."
Note:
Score:	4.0
Pubmed(PMID):	19530246
Sentence Index:	19530246_3-4
Sentence:	"We found that HKH40A activated ataxia telangiectasia mutated (ATM) kinase, which then triggered activation of the Chk1/2 signaling pathway, evidenced by Chk1/2 mediated inhibitory phosphorylation of Cdc25C protein phosphatase. This resulted in Cdk1 tyrosine phosphorylation at Tyr-15, leading to cell cycle block at G2/M phase."

Sequence & Structure:

MSTELFSSTREEGSSGSGPSFRSNQRKMLNLLLERDTSFTVCPDVPRTPVGKFLGDSANLSILSGGTPKRCLDLSNLSSGEITATQLTTSADLDETGHLDSSGLQEVHLAGMNHDQHLMKCSPAQLLCSTPNGLDRGHRKRDAMCSSSANKENDNGNLVDSEMKYLGSPITTVPKLDKNPNLGEDQAEEISDELMEFSLKDQEAKVSRSGLYRSPSMPENLNRPRLKQVEKFKDNTIPDKVKKKYFSGQGKLRKGLCLKKTVSLCDITITQMLEEDSNQGHLIGDFSKVCALPTVSGKHQDLKYVNPETVAALLSGKFQGLIEKFYVIDCRYPYEYLGGHIQGALNLYSQEELFNFFLKKPIVPLDTQKRIIIVFHCEFSSERGPRMCRCLREEDRSLNQYPALYYPELYILKGGYRDFFPEYMELCEPQSYCPMHHQDHKTELLRCRSQSKVQEGERQLREQIALLVKDMSP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CDC25C-Ser168
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC
GBM
HNSC	0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CDC25C-Ser216
Cancer	Intensity
BRCA	0.236
COAD
HGSC
ccRCC
GBM	0.481
HNSC	0.035
LUAD	-0.999
LUSC	-1.233
non_ccRCC
PDAC
UCEC	1.48

CDC25C-Ser263
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

CDC25C-Thr48
Cancer	Intensity
BRCA	-0.88
COAD
HGSC	1.793
ccRCC
GBM	0.534
HNSC	-0.09
LUAD	-0.562
LUSC	-1.134
non_ccRCC
PDAC
UCEC	0.339

CDC25C-Tyr165
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	P	Leukemia	Phosphorylation	11202906
S	216	U	Colorectal carcinoma	Phosphorylation	35999268
S	216	U	High-grade serous ovarian carcinoma	Phosphorylation	35017636

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb